Skip to main content

Table 4 Effect of rs12979860 genotype on percentage sustained viral response for boceprevir and telaprevir treatment regimes

From: Pharmacogenomics of hepatitis C infections: personalizing therapy

Treatment Genotype (%SVR)
  CC CT TT
SPRINT-2 (n = 653)    
PegIFN/R 78 28 27
BOC/RGT 82 65 55
BOC/PR48 80 71 59
No HCV at 8 weeks 89 52
ADVANCE (n = 454)    
PegIFN/R 64 25 23
T8 24/48 84 57 59
T12 24/48 90 71 73
No HCV at 4 and 12 weeks 72 52
  1. %SVR, percentage sustained viral response. Data from SPRINT-2 (boceprevir, BOC) [49] and ADVANCE (telaprevir, T) clinical trials [50]. SPRINT-2 regime: PegIFN/R for 48 weeks. BOC/RGT: PegIFN/R for 4 weeks, then 24 weeks; BOC and PegIFN/R if HCV undetectable, 44 weeks if not. BOC/PR48: PegIFN/R for 4 weeks, then 44 weeks BOC and PegIFN/R. No hepatitis C virus (HCV) based on detection at 8 weeks. ADVANCE regime: PegIFN/R for 48 weeks. T8 24/48: telaprevir for 8 weeks, PegIFN/R for 24 or 48 weeks, dependent on HCV at 4 and 12 weeks. T12 24/48: telaprevir for 12 weeks, PegIFN/R for 24/48 weeks. No HCV based on detection at 4 and 12 weeks of treatment.